Blood Coagulation and Fibrinolysis in Thyroid Disease

Nadir R. Farid; Brian L. Griffiths; John R. Collins; William H. Marshall; David Wallace Ingram

doi:10.1055/s-0038-1647936

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1976; 35(02): 415-422
DOI: 10.1055/s-0038-1647936

Original Article

Schattauer GmbH

Blood Coagulation and Fibrinolysis in Thyroid Disease

Authors

Nadir R. Farid

¹General Hospital and The Faculty of Medicine Memorial University of Newfoundland St. John’s, Newfoundland, Canada A1C 5S7
Brian L. Griffiths

¹General Hospital and The Faculty of Medicine Memorial University of Newfoundland St. John’s, Newfoundland, Canada A1C 5S7
John R. Collins

¹General Hospital and The Faculty of Medicine Memorial University of Newfoundland St. John’s, Newfoundland, Canada A1C 5S7
William H. Marshall

¹General Hospital and The Faculty of Medicine Memorial University of Newfoundland St. John’s, Newfoundland, Canada A1C 5S7
David Wallace Ingram

¹General Hospital and The Faculty of Medicine Memorial University of Newfoundland St. John’s, Newfoundland, Canada A1C 5S7

Abstract

Summary

Fibrinolytic activity and factor VIII concentration were studied in 30 patients with moderate to minimal hypothyroidism and in 7 patients with hyperthyroidism. In the hypothyroid group, the results were related to serum thyroxine levels, HL-A phenotypes and thyroid autoantibody titres. As serum thyroxine decreased so did factor VIII concentration, however, euglobulin lysis time was correspondingly prolonged. Factor VIII appears to be the most sensitive among coagulation factors to the deterioration of thyroid function tests. There was a significant correlation between the reciprocal of thyroid antibody titres and fibrinolysis; however, there was no relationship between factor VIII concentration or fibrinolysis and a specific HL-A phenotype although the incidence of HL-A8 was increased in the group as a whole.

Euglobulin lysis time was prolonged in 6 out of 7 patients with Graves’ hyperthyroidism. Factor VIII was elevated in only 3 of these patients.

Volltext

Referenzen

References
1 Allington J. J. 1971; Detection of fibrin(ogen) degradation products by a latex clumping method. Scandinavian Journal of Haematology. Supplement 13: 115.
2 Bastenie P. S, Van Haelst L, Neve P. 1972. Thyroiditis and Thyroid Function. Pergamon Press; New York: 275.
3 Biggs R. 1972. Human blood coagulation, haemostasis and thrombosis. Blackwell Scientific Publication; London: 634
4 Borhani O. N. 1972; Endocrine Factors and Venous Thrombosis. The Milk Bank Memorial Fund Quarterly p. 50, 1 (02) 31.
5 Buckell M. 1958; The Effect of citrate on euglobulin methods of estimating fibrinolytic activity. Journal of Clinical Pathology 11: 403.
6 Dinternfass L, Stewart J. W, Milton G. W, Forbes C. D. 1973; The influence of ABO blood groups and fibrinogen on thrombus formation and aggregation of red cells in cardiovascular and malignant diseases. New aspects of biorheological characterization of disease. Biorheology 10: 585.
7 Doniach D. 1967; Thyroid auto-immune disease. Journal of Clinical Pathology-Supplement 20: 385.
8 Edson J. R, Fecher D. R, Doe R. P. 1975; Low platelet adhesiveness and other hemostatic abnormalities in hypothyroidism. Annals of Internal Medicine 82: 342.
9 Egeberg O. 1963; Influence of thyroid function on blood clotting system. Scandinavian Journal of Clinical and Laboratory Investigation 15: 1.
10 Evered D. C, Hall R. 1973; Grades of hypothyroidism. British Medical Journal 3: 695.
11 Farid N. R, Barnard J, Kutas C, Noel E. P, Marshall W. H. 1975; HL-A antigens in Graves’ Disease and Hashimoto’s thyroiditis. International Archives of Allergy and Applied Immunology 49: 837.
12 Grumet C. F, Payne R. O, Konishi J, Kriss J. P. 1974; HL-A antigens as markers for disease susceptibility and autoimmunity in Graves’ disease. Journal of Clinical Endocrinology and Metabolism 39: 1115.
13 Hardisty R. M, MacPherson J. C. 1962; A one-stage Factor VIII (antihaemphilic globulin) assay and its use on venous and capillary plasma. Thrombosis et Diathesis Haemorrhagica 7: 215.
14 Korsan-Bengsren K, Thor-Bjorn C. 1974; Influence of two different Beta-Adrenergic Blocking agents on the increase in fibrinolytic activity and factor VIII activity during submaximum and maximum exercise. Scandinavian Journal of Haematology 13: 311.
15 Masi A. T. 1972; Endocrine factors and risk of venous thrombosis. Milbank Memorial Fund Quarterly 50 (01) Supl. 2: 46.
16 Matthews J. D, Whtttingham S, Mackay I. R. 1974; Autoimmune mechanisms in human vascular disease. Lancet 77: 1423.
17 Mittal K. K, Mickey M. R, Singal P. F, Teresaki P. I. 1968; Serotyping for homo transplantation. Transplantation 6: 913.
18 Murphy B. E. P, Pattee C. J, Gold A. 1966; Clinical evaluation of a new method for determination of serum thyroxine. Journal of Clinical Endocrinology and Metabolism 26: 247.
19 Napiorkowska W, Palester-Cheebowezyk M, Keydana-Jedrzejewska B, Strzysewska E. 1972; The pattern of blood clotting and fibrinolytic systems in hyperthyreosis. Endokrynologia Polska 23: 423.
20 Odell W. D, Utiger R. D, Wilber J. 1967; Studies of thyrotrophin physiology by means of radioimmunoassays. Recent Progress in Hormonal Research 23: 47.
21 Ormston B. J, Garry R, Cyrer R. J, Besser G. M, Hall R. 1971; Thyrotrophin Releasing Hormone as a thyroid function test. Lancet II: 10.
22 Owren P. A. 1959; Thrombotest. A. new method for controlling anticoagulant therapy. Lancet 17: 754.
23 Panchenko V. M, Antonidze A. V. 1973; Blood Coagulation in patients with toxic goiter. Problem Endokrinologii (Moskva) 19: 22.
24 Simone J. V, Abtlgaard C. F, Scholman I. 1965; Blood coagulation in thyroid dysfunction. The New England Journal of Medicine 273: 1057.
25 Sisson J. V. 1965; Principles of and pitfalls in thyroid function tests. Journal of Nuclear Medicine 6: 853.